- Home
- PIII vs COCP Comparison
PIII vs COCP Comparison
Compare PIII & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | COCP |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 15.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | COCP |
|---|---|---|
| Price | $5.30 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.25 | $6.00 |
| AVG Volume (30 Days) | 9.8K | ★ 71.8K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.97 | $0.90 |
| 52 Week High | $14.50 | $3.26 |
Technical Indicators
Market Signals| Indicator | PIII | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 29.58 | 48.33 |
| Support Level | $5.14 | $1.00 |
| Resistance Level | $5.62 | $1.08 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 9.86 | 72.50 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).